Scancell Holdings

SCLP.L

Biotechnology · Healthcare

Exchange

London Stock Exchange

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Track this stock — start free trial

Winston Score History

The full picture

Scancell Holdings is a small British biotech company that develops experimental cancer vaccines and immunotherapies. Its main focus is teaching the immune system to recognize and attack cancer cells, with lead programs targeting melanoma and other solid tumors. The company does not yet sell any approved products — all of its work is in clinical trials, meaning it is still testing whether its treatments are safe and effective in patients.

Scancell earns almost no revenue today and funds its research primarily through equity fundraising and grants. It is based in Nottingham, UK, and operates at a significant loss, which is typical for early-stage drug developers. Its technology platforms, called Moditope and SCIB1, are designed to trigger strong immune responses, but the central risk is that clinical trials may fail, which would destroy the value of years of research and require the company to raise more cash just to survive.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

Revenue data limited

EPS Growth

+105.4% YoY

YoY Growth Rate

EPS growth accelerating

Insider Activity

3.1%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Runway

~3 years

£17M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

£17M cash & investments at current burn rate

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

N/A

Data not available

Profit after running costs

Operating Margin

N/A

Data not available

Return on the money invested

ROCE

-118.7%

Weak — -118.7% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

N/A

Data not available

Profit growth

EPS YoY

N/A

Data not available

How steady the profit is

EPS Consistency

5/8 quarters

Mixed — about half the quarters showed growth

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

Data not available

Spare cash per sale

FCF Margin

-177.5%

Burning cash (-177.5%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

N/A

Data not available

Covers its interest

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

no trend

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial